Improved PFS With Addition of Idelalisib to Ofatumumab in Previously Treated CLL

May 29-June 2, 2015; Chicago, Illinois
Results of an open-label phase III trial investigating the safety and efficacy of adding idelalisib to ofatumumab in pretreated CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 694 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

CME-certified Webcast of a CCO symposium at ASH 2019 featuring expert perspectives on current optimal management of patients with PTCL

Francine Foss, MD Steven M. Horwitz, MD Barbara Pro, MD Physicians: maximum of 2.5 AMA PRA Category 1 Credits Released: January 27, 2020 Expiration: January 26, 2021

Michael Heuser, MD, reviews key studies in the management of leukemias from 2019 ASH for Clinical Care Options (CCO)

person default Michael Heuser, MD Released: January 24, 2020

In this Clinical Care Options (CCO) expert commentary, Jeff P. Sharman, MD, provides his thoughts on key studies in CLL and lymphomas that were presented at ASH 2019.

Jeff P. Sharman, MD Released: January 23, 2020

Expert commentary with practical insights on the recent FDA approval and use of acalabrutinib in CLL from Clinical Care Options (CCO)

Nicole Lamanna, MD Released: January 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?